BCM
COCH icon

BlueCrest Capital Management’s Envoy Medical COCH Stock Holding History

BlueCrest Capital Management’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,000
Closed -$3.01M – 262
2022
Q4 		$3.01M Hold
300,000
– – 0.08% 85
2022
Q3 		$2.95M Buy
+300,000
New +$2.95M 0.09% 95

Other funds holding COCH

AMC
Atlas Merchant Capital New York $789K AUM 60.67% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BlueCrest Capital Management's COCH Position: Q1 2023 in Review

BlueCrest Capital Management sold out of Envoy Medical (COCH) in Q1 2023, closing a stake of 300,000 shares — an estimated $3.01M sold.

BlueCrest Capital Management first reported a position in COCH in Q3 2022 and held it in 2 quarters. The position peaked at $3.01M in Q4 2022. 24 funds tracked by Wall St. Rank hold COCH as of Q1 2023.

  • BlueCrest Capital Management reported no remaining Envoy Medical position as of Q1 2023 after selling out during the quarter.
  • BlueCrest Capital Management sold 300,000 Envoy Medical shares in Q1 2023, an estimated $3.01M.
  • BlueCrest Capital Management first reported a position in Envoy Medical in Q3 2022 and held it in 2 quarters.
  • BlueCrest Capital Management's Envoy Medical position peaked at $3.01M in Q4 2022.
  • 24 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2023.

Based on BlueCrest Capital Management's 13F filing for Q1 2023, filed 15 May 2023.